WT1 and acute myeloid leukemia: Chapuis et al. used adoptive transfer of WT1-specific allogeneic TCR-T cells in a clinical trial to treat high-risk AML patients, achieving good therapeutic outcomes and helping to prevent disease relapse (NCT01640301) [138].